logo

Alecinix

Alectinib is a kinase inhibitor indicated for the treatment of adult patients with anaplastic lymphoma kinase (ALK)-positive advanced non-small cell lung cancer (NSCLC) who have progressed on or are intolerant to Crizotinib.

Alectinib as monotherapy is indicated for the first-line treatment of adult patients with anaplastic lymphoma kinase (ALK)-positive advanced non-small cell lung cancer (NSCLC).

Features

Name Alecinix
Generic Name Alectinib
Formulation Capsule
Available Pack Size 3x10's Alu-Alu
Available Strength 40 mg
View Prescribing Information Visit Website